Paradigm Biopharmaceuticals Forges Ahead in Animal Health with Novel Osteoarthritis Therapy
Paradigm Biopharmaceuticals (ASX: PAR) has announced a significant strategic move, entering into a binding term sheet with AVet Health to jointly develop and license a groundbreaking oral combination therapy for companion animal osteoarthritis (OA). This collaboration marks a pivotal step for Paradigm, allowing them to advance a promising asset in the burgeoning animal health sector while maintaining their unwavering focus on the critical Phase 3 PARA_OA_012 clinical trial for human knee osteoarthritis.
The innovative therapy centres on a novel combination of pentosan polysulfate sodium (PPS) and a COX-2 inhibitor. This dual-action approach aims to address the debilitating effects of osteoarthritis, a condition that significantly impacts the quality of life for countless pets worldwide.
Paul Rennie, Managing Director of Paradigm Biopharmaceuticals, highlighted the strategic advantages of this agreement. “This agreement provides Paradigm with a clear pathway to progress this promising asset in the animal health sector,” he stated. “Crucially, it allows us to generate early formulation and preclinical data that can expedite the veterinary regulatory pathway through the APVMA, while also contributing valuable data to our longer-term regulatory submission for human use.”
Rennie further emphasised the capital-efficient nature of this venture. “Importantly, this is being undertaken in a capital-efficient manner, enabling Paradigm to remain fully focused on our pivotal Phase 3 clinical trial of Zilosul and our ongoing commercial interests as we prepare for the interim analysis,” he explained. This strategic approach ensures that the company’s resources are optimally allocated to its most critical human health initiatives.
The intellectual property underpinning this novel PPS and COX-2 inhibitor combination was acquired by Paradigm in 2025, forming part of a deliberate expansion of their osteoarthritis portfolio. This acquisition was a cornerstone in their strategy to develop an oral, non-opioid therapy for osteoarthritis, targeting both veterinary and human health applications, with a particular emphasis on addressing earlier stages of the disease.
“This oral formulation represents a first-in-class approach,” Rennie elaborated. “It combines PPS, a compound with demonstrable disease-modifying potential, with a COX-2 inhibitor designed to effectively reduce inflammation and pain. This dual-action candidate distinguishes itself from existing injectable PPS products available in the veterinary market, potentially offering enhanced convenience, improved safety profiles, and greater compliance for animals requiring long-term OA management.”
A Collaborative Approach to Veterinary Development
Paradigm will spearhead the funding for the veterinary development program, which will unfold through a multi-stage plan. The initial phase, Stage 1, encompassing formulation development and preliminary non-clinical studies, is projected to incur costs of approximately $1 million.
AVet Health is set to make a substantial contribution to this initial development phase through in-kind resources. This includes vital project management and scientific oversight, alongside the provision of supply and access to the Drug Master File for commonly utilised COX-2 inhibitors within the veterinary sector.
AVet Health is a well-established veterinary pharmaceutical company with an impressive track record, having successfully registered over 95 products with the Australian Pesticides and Veterinary Medicines Authority (APVMA). This extensive experience and regulatory expertise will be invaluable in navigating the path to market for the new combination therapy.
Osteoarthritis continues to be a prevalent and debilitating condition for companion animals, leading to significant pain and diminished mobility. The development of an effective and convenient oral treatment could revolutionise the management of this widespread ailment, significantly improving the well-being of beloved pets.
Paradigm Biopharmaceuticals (ASX: PAR) has seen its share price rise by 3.45% to 30.0c, with a market capitalisation of $124.2 million. This development underscores the company’s commitment to innovation across both human and animal health sectors.
